Crestline Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-713,205	Closed	-$9.43M	–	546
2024 Q4	$9.43M	Buy	713,205 +284,667	+66%	+$4.87M	0.31%	54
2024 Q3	$8.25M	Buy	428,538 +285,258	+199%	+$5.89M	0.43%	59
2024 Q2	$2.94M	Buy	143,280 +39,570	+38%	+$828K	0.23%	115
2024 Q1	$2.47M	Buy	103,710 +3,061	+3%	+$68.3K	0.22%	122
2023 Q4	$2.18M	Sell	100,649 -33,815	-25%	-$520K	0.19%	130
2023 Q3	$1.95M	Buy	134,464 +22,000	+20%	+$416K	0.23%	110
2023 Q2	$2.35M	Buy	112,464 +17,255	+18%	+$359K	0.25%	107
2023 Q1	$2.01M	Buy	95,209 +31,002	+48%	+$771K	0.24%	99
2022 Q4	$1.63M	Buy	64,207 +656	+1%	+$15.3K	0.24%	79
2022 Q3	$1.53M	Buy	63,551 +3,000	+5%	+$67.3K	0.21%	92
2022 Q2	$1.17M	Sell	60,551 -2,965	-5%	-$49.4K	0.15%	111
2022 Q1	$1.1M	Buy	+63,516	New	+$1.07M	0.13%	134
2018 Q3	–	Sell	-35,027	Closed	-$246K	–	226
2018 Q2	$246K	Sell	35,027 -1,687	-5%	-$16.6K	0.03%	228
2018 Q1	$522K	Sell	36,714 -46,425	-56%	-$493K	0.06%	192
2017 Q4	$728K	Buy	83,139 +29,607	+55%	+$293K	0.07%	127
2017 Q3	$626K	Sell	53,532 -1,836	-3%	-$22.5K	0.09%	117
2017 Q2	$773K	Buy	+55,368	New	+$633K	0.1%	98